This inventor holds 1 USPTO granted patent. Top assignee: Snu Rdb Foundation. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Innovations of Hyungki Lee in Genetic Engineering
Introduction
Hyungki Lee is a notable inventor based in Suwon, South Korea. He has made significant contributions to the field of genetic engineering, particularly in the development of shuttle vectors for mycobacteria and Escherichia coli. His work has implications for gene delivery systems and therapeutic applications.
Latest Patents
Hyungki Lee holds a patent for "Shuttle vectors for mycobacteria-escherichia coli and uses thereof." This patent describes a DNA molecule capable of replication, featuring a nucleic acid sequence as disclosed in SEQ ID NO: 1. The shuttle vector constructed using this DNA molecule is approximately 18 kb in size and contains 16 open reading frames (ORFs), a replication origin, and a rep-like protein essential for replication. This plasmid can be utilized as a gene delivery system for research and therapeutic applications, effectively delivering proteins or heterologous DNA and expressing the encoded DNA in cells.
Career Highlights
Hyungki Lee is associated with the SNU RDB Foundation, where he continues to advance his research in genetic engineering. His innovative work has garnered attention in the scientific community, contributing to advancements in gene therapy and molecular biology.
Collaborations
Hyungki Lee collaborates with Bum-Joon Kim, a fellow researcher, to further explore the applications of his patented technologies. Their partnership enhances the potential for breakthroughs in genetic research and therapeutic solutions.
Conclusion
Hyungki Lee's contributions to genetic engineering through his innovative patents and collaborations highlight the importance of research in advancing medical and scientific knowledge. His work continues to pave the way for future developments in gene therapy and molecular biology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
